# Adaptive Immune Response to COVID-19 Vaccination

> **NCT04826770** · — · UNKNOWN · sponsor: **University Medicine Greifswald** · enrollment: 70 (actual)

## Conditions studied

- SARS-CoV-2 Vaccination

## Interventions

- **DRUG:** BNT162b2
- **DRUG:** AZD 1222
- **DRUG:** mRNA-1273

## Key facts

- **NCT ID:** NCT04826770
- **Lead sponsor:** University Medicine Greifswald
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-06
- **Primary completion:** 2021-12-13
- **Final completion:** 2023-12-31
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2023-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04826770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04826770, "Adaptive Immune Response to COVID-19 Vaccination". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04826770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*